Antithrombotic and restenosis blood vessel bracket and method for preparing the same

A technology for restenosis and antithrombosis, applied in the fields of medical science, surgery, coating, etc., can solve the problems of failure to inhibit thrombosis and restenosis, hinder stent endothelialization, etc., achieve excellent anticoagulant performance, inhibit pathology, etc. Sexual proliferation and migration, the effect of inhibiting proliferation

Inactive Publication Date: 2008-06-11
ARMY MEDICAL UNIV +1
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Since the placement of stents cannot fundamentally change the pathogenic environment of the body, pathogenic factors such as hyperlipidemia and hyperglycemia in patients can affect the impla

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Embodiment 1. Vascular stent material acquisition:

[0030]Made of 316L low-carbon stainless steel, tantalum, nickel-titanium memory alloy, or directly using various existing bracket materials

Embodiment 2

[0031] Example 2 Surface Modification of Vascular Stents A20 and CD34 Antibodies

[0032] Adjust bovine collagen 4mg / ml to pH 7.14, add cross-linking agent EDAC (0.1-0.2mg / mg collagen), soak the scaffold in the collagen solution for a while, take it out, dry it at 37°C, repeat several times to each The surface of the stent is coated with 30~60mg / cm 2 Collagen. In order to evaluate the collagen coating of the stents, 1-2 stents after coating and stents after in vitro balloon expansion were taken for observation by scanning electron microscope. It can be seen that the collagen adheres evenly on the scaffold.

[0033] After coating, the stent was placed in SPDP solution (15-25mmol / L, DMSO:PBS=1:1), and reacted at room temperature for 1-3h. The stent connected with SPDP was washed with PBS and then reacted with DTT at room temperature for 0.5-1h, and washed with PBS for 5 hours. all over. Then put the specific mouse anti-bovine DNA monoclonal antibody (IgM-SPDP) and the CD34 a...

Embodiment 3

[0035] Example 3 Surface Modification of Vascular Stents A20 and CD133 Antibodies

[0036] Adjust bovine collagen 4mg / ml to pH 7.14, add cross-linking agent EDAC (0.1-0.2mg / mg collagen), soak the scaffold in the collagen solution for a while, take it out, dry it at 37°C, repeat several times to each The surface of the stent is coated with about 30~60mg / cm 2 Collagen. In order to evaluate the collagen coating of the stents, 1-2 stents after coating and stents after external balloon expansion were taken and observed by scanning electron microscope. It can be seen that the collagen adheres evenly on the scaffold.

[0037] After coating, the stent was placed in SPDP solution (15-25mmol / L, DMSO:PBS=1:1), and reacted at room temperature for 1-3h. The stent connected with SPDP was washed with PBS and then reacted with DTT at room temperature for 0.5-1h, and washed with PBS for 5 hours. all over. Then put the specific mouse anti-bovine DNA monoclonal antibody (IgM-SPDP) and the CD...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an effectively anti-thrombotic restenosis blood vessel inner support, and comprises a blood vessel inner support body. The invention is characterized in that the surface of the support body has a surface modifying layer which has A20 or A20 and correlation factors which can capture auto-endothelial progenitor cells in vivo, the A20 is A20 eukaryotic expression carriers, viral vectors, or A20 protein, and the correlation factors which can capture auto-endothelial progenitor cells in vivo are selected from esoderma growth factor II type receptor KDR antibodies, CD34 antibodies, or CD133 antibodies. The invention further relates to the process for preparing the support, the support can in vivo induce the endothelial progenitor cells and endothelial cells in the circulating blood to plant, and inhibit smooth muscle cells from breeding, and the performances of antithrombotic formation and anti-vessel restenosis are provided. The invention is used in the support plasty after the blood vessel is clinically provided with restenosis.

Description

technical field [0001] The invention relates to a surface modification method of an intravascular stent capable of effectively resisting thrombus and restenosis. technical background [0002] As a solution to restenosis after percutaneous transluminal angioplasty (PTA), intravascular stent has been widely used in clinical treatment of coronary heart disease and cerebrovascular disease, and can significantly improve the incidence of restenosis in the near future. However, in the long-term effect, stent implantation cannot completely inhibit the neointimal hyperplasia. For patients with diabetes and some special vulnerable parts (such as vascular bifurcations, long-term high-pressure perfusion and / or small blood vessels), in-stent restenosis The incidence rate is still as high as 30% to 60%. Therefore, stent-derived thrombosis and in-stent restenosis have become problems to be solved in the application of stents. [0003] The currently used stent materials are mainly 316L lo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61L31/12A61L31/02A61L31/04A61L31/10A61L31/16
Inventor 朱楚洪周振华曾文
Owner ARMY MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap